Nora Luethi

Nora Luethi

Auto-generated profile, based on publicly available information

Nora Luethi

Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2020 in JAMA
Verified
Journal Article
Open access
PDF file
TFTomoko Fujii
Tomoko Fujii
NLNora Luethi
Nora Luethi
PYPaul J. Young
Paul J. Young
DFDaniel R. Frei
Daniel R. Frei
GEGlenn M. Eastwood
Glenn M. Eastwood
FIfor the VITAMINS Trial Investigators
for the VITAMINS Trial Investigators
Sepsis is a life-threatening illness characterized by a dysregulated host response to infection.1 It causes or contributes to between one-third and half of all hospital deaths2 and is responsible for more than 5 million deaths worldwide each year.3 Patients with septic shock are an important sepsis subgroup and have circulatory and metabolic abnormalities that substantially increase their mortality risk.4 For these patients in particular, new treatments that improve outcomes are a global public health priority.

21 October 2018 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
JMJohan Mårtensson
Johan Mårtensson
SBShailesh Bihari
Shailesh Bihari
JBJonathan Bannard-Smith
Jonathan Bannard-Smith
NGNeil J. Glassford
Neil J. Glassford
PLPatryck Lloyd-Donald
Patryck Lloyd-Donald
RBRinaldo Bellomo
Rinaldo Bellomo

1 June 2018 in Critical Care Medicine
Verified
Journal Article
Closed access
NLNora Luethi
Nora Luethi
LCLuca Cioccari
Luca Cioccari
PBPeter Biesenbach
Peter Biesenbach
LLLuca Lucchetta
Luca Lucchetta
HKHidetoshi Kagaya
Hidetoshi Kagaya
JMJohan Mårtensson
Johan Mårtensson
Objectives: To assess the feasibility, biochemical efficacy, and safety of liberal versus conventional glucose control in ICU patients with diabetes. Design: Prospective, open-label, sequential period study. Setting: A 22-bed mixed ICU of a tertiary hospital in Australia. Patients: We compared 350 consecutive patients with diabetes admitted over 15 months who received liberal glucose control with a preintervention control population of 350 consecutive patients with diabetes who received conventional glucose control. Interventions: Liberal control patients received insulin therapy if glucose was greater than 14 mmol/L (target: 10–14 mmol/L [180–252 mg/dL]). Conventional control patients received insulin therapy if glucose was greater than 10 mmol/L (target: 6–10 mmol/L [108–180 mg/dL]). Measurements and Main Results: We assessed separation in blood glucose, insulin requirements, occurrence of hypoglycemia (blood glucose ≤ 3.9 mmol/L [70 mg/dL]), creatinine and white cell count levels, and clinical outcomes. The median (interquartile range) time-weighted average blood glucose concentration was significantly higher in the liberal control group (11.0 mmol/L [8.7–12.0 mmol/L]; 198 mg/dL [157–216 mg/dL]) than in the conventional control group (9.6 mmol/L [8.5–11.0 mmol/L]; 173 mg/dL [153–198 mg/dL]; p < 0.001). Overall, 132 liberal control patients (37.7%) and 188 conventional control patients (53.7%) received insulin in ICU (p < 0.001). Hypoglycemia occurred in 6.6% and 8.6%, respectively (p = 0.32). Among 314 patients with glycated hemoglobin A1c greater than or equal to 7%, hypoglycemia occurred in 4.1% and 9.6%, respectively (p = 0.053). Trajectories of creatinine and white cell count were similar in the groups. In multivariable analyses, we found no independent association between glucose control and mortality, duration of mechanical ventilation, or ICU-free days to day 30. Conclusions: In ICU patients with diabetes, during a period of liberal glucose control, insulin administration, and among patients with hemoglobin A1c greater than or equal to 7%, the prevalence of hypoglycemia was reduced, without negatively affecting serum creatinine, the white cell count response, or other clinical outcomes. (Trial Registration: Australian New Zealand Clinical Trials Registry; ACTRN12615000216516).

1 September 2016 in Critical Care Medicine
Verified
Journal Article
Closed access
NLNora Luethi
Nora Luethi
LCLuca Cioccari
Luca Cioccari
ATAiko Tanaka
Aiko Tanaka
PKPalash Kar
Palash Kar
EGEmma Giersch
Emma Giersch
RBRinaldo Bellomo
Rinaldo Bellomo
Objectives: Glycated hemoglobin A1c is used to estimate glycemic control. However, its value upon ICU admission may be altered by critical illness and not reflect true glycemic status. We assessed the relationship between ICU admission glycated hemoglobin A1c and premorbid glycated hemoglobin A1c levels. Design: Retrospective observational cohort study. Setting: Two tertiary ICUs in Australia. Patients: Cohort of 69 critically ill patients with diabetes and glycated hemoglobin A1c levels measured upon ICU admission and during the month prior to admission. Interventions: Measurement of glycated hemoglobin A1c. Measurements and Main Results: Mean (sd) glycated hemoglobin A1c level was 7.5% (1.8%) upon ICU admission and 7.8% (2.0%) in previous measurements from the preceding 30 days. The change in glycated hemoglobin A1c did not correlate with time elapsed between the two measurements (r 2 = 0.00005; p = 0.95), but there was a strong correlation between admission glycated hemoglobin A1c levels and premorbid glycated hemoglobin A1c levels (r 2 = 0.89; p < 0.001). Conclusions: Glycated hemoglobin A1c levels are not altered by the onset of critical illness. Glycated hemoglobin A1c quantified at ICU admission can, therefore, be used to reliably estimate chronic glycemic control and guide acute glycemic therapy.

25 November 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LCLuca Cioccari
Luca Cioccari
NLNora Luethi
Nora Luethi
Mojgan MasoodiMojgan Masoodi
Mojgan Masoodi
A dysregulated response to systemic inflammation is a common pathophysiological feature of most conditions encountered in the intensive care unit (ICU). Recent evidence indicates that a dysregulated inflammatory response is involved in the pathogenesis of various ICU-related disorders associated with high mortality, including sepsis, acute respiratory distress syndrome, cerebral and myocardial ischemia, and acute kidney injury. Moreover, persistent or non-resolving inflammation may lead to the syndrome of persistent critical illness, characterized by acquired immunosuppression, catabolism and poor long-term functional outcomes. Despite decades of research, management of many disorders in the ICU is mostly supportive, and current therapeutic strategies often do not take into account the heterogeneity of the patient population, underlying chronic conditions, nor the individual state of the immune response. Fatty acid-derived lipid mediators are recognized as key players in the generation and resolution of inflammation, and their signature provides specific information on patients’ inflammatory status and immune response. Lipidomics is increasingly recognized as a powerful tool to assess lipid metabolism and the interaction between metabolic changes and the immune system via profiling lipid mediators in clinical studies. Within the concept of precision medicine, understanding and characterizing the individual immune response may allow for better stratification of critically ill patients as well as identification of diagnostic and prognostic biomarkers. In this review, we provide an overview of the role of fatty acid-derived lipid mediators as endogenous regulators of the inflammatory, anti-inflammatory and pro-resolving response and future directions for use of clinical lipidomics to identify lipid mediators as diagnostic and prognostic markers in critical illness.

1 December 2019 in Critical Care and Resuscitation
Verified
Journal Article
Open access
EHElizabeth P. Hudson
Elizabeth P. Hudson
JCJake T.B. Collie
Jake T.B. Collie
TFTomoko Fujii
Tomoko Fujii
NLNora Luethi
Nora Luethi
AUAndrew A. Udy
Andrew A. Udy
RBRinaldo Bellomo
Rinaldo Bellomo
Objectives: To study vitamin C pharmacokinetics in septic shock. Design: Prospective pharmacokinetic study. Setting: Two intensive care units. Participants: Twenty-one patients with septic shock enrolled in a randomised trial of high dose vitamin C therapy in septic shock. Intervention: Patients received 1.5 g intravenous vitamin C every 6 hours. Plasma samples were obtained before and at 1, 4 and 6 hours after drug administration, and vitamin C concentrations were measured by high performance liquid chromatography. Main outcome measures: Clearance, volume of distribution, and half-life were calculated using noncompartmental analysis. Data are presented as median (interquartile range [IQR]). Results: Of the 11 participants who had plasma collected before any intravenous vitamin C administration, two (18%) were deficient (concentrations < 11 μmol/L) and three (27%) had hypovitaminosis C (concentrations between 11 and 23 μmol/L), with a median concentration 28 μmol/L (IQR, 11–44 μmol/L). Volume of distribution was 23.3 L (IQR, 21.9–27.8 L), clearance 5.2 L/h (IQR, 3.3–5.4 L/h), and half-life 4.3 h (IQR, 2.6–7.5 h). For the participants who had received at least one dose of intravenous vitamin C before sampling, T0 concentration was 258 μmol/L (IQR, 162– 301 μmol/L). Pharmacokinetic parameters for subsequent doses were a median volume of distribution 39.9 L (IQR, 31.4–44.4 L), clearance 3.6 L/h (IQR, 2.6–6.5 L/h), and halflife 6.9 h (IQR, 5.7–8.5 h). Conclusion: Intravenous vitamin C (1.5 g every 6 hours) corrects vitamin C deficiency and hypovitaminosis C and provides an appropriate dosing schedule to achieve and maintain normal or elevated vitamin C levels in septic shock.